Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACZ885 in SJIA
NCT00426218Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2006
- Primary completion
- Mar 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of canakinumab in systemic juvenile idiopathic arthritis (SJIA), sponsored by Novartis. Started Dec 2006; status: completed.
02
Drugs
canakinumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on NCT00426218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00426218.